Theravance Biopharma (TBPH) Net Cash Flow Growth (5y) (2019 - 2026)
Theravance Biopharma (TBPH) Net Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Theravance Biopharma | 866.36 Mn | 471.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.88% |
| Dec 31, 2025 | -27.72% |
| Sep 30, 2025 | -56.39% |
| Jun 30, 2025 | 22.43% |
| Mar 31, 2025 | -23.32% |
| Dec 31, 2024 | 17.90% |
| Sep 30, 2024 | 19.61% |
| Jun 30, 2024 | 30.11% |
| Mar 31, 2024 | 15.91% |
| Dec 31, 2023 | -16.17% |
| Sep 30, 2023 | -66.48% |
| Jun 30, 2023 | -30.15% |
| Mar 31, 2023 | -37.97% |
| Dec 31, 2022 | 104.71% |
| Sep 30, 2022 | -73.43% |
| Jun 30, 2022 | 25.25% |
| Mar 31, 2022 | 15.16% |
| Dec 31, 2021 | -16.24% |
| Sep 30, 2021 | -6.21% |
| Jun 30, 2021 | 35.98% |